Trial Profile
Evaluation of the Efficacy and Continuance Rate of Treatment in Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 08 Mar 2019 Status changed from recruiting to completed.
- 19 Jul 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 10 Jul 2014 New trial record